HM Payson & Co. cut its stake in Becton, Dickinson and Company (NYSE:BDX) by 0.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 74,294 shares of the medical instruments supplier’s stock after selling 389 shares during the period. HM Payson & Co.’s holdings in Becton, Dickinson and were worth $13,628,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Hendley & Co. Inc. raised its stake in Becton, Dickinson and by 10.7% in the first quarter. Hendley & Co. Inc. now owns 7,766 shares of the medical instruments supplier’s stock valued at $1,425,000 after buying an additional 750 shares during the last quarter. Achmea Investment Management B.V. acquired a new stake in Becton, Dickinson and during the first quarter valued at about $4,541,000. Community Trust & Investment Co. acquired a new stake in Becton, Dickinson and during the first quarter valued at about $271,000. Cambridge Trust Co. raised its stake in Becton, Dickinson and by 22.3% in the first quarter. Cambridge Trust Co. now owns 118,083 shares of the medical instruments supplier’s stock valued at $21,661,000 after buying an additional 21,535 shares during the last quarter. Finally, Bank of Nova Scotia raised its stake in Becton, Dickinson and by 92.0% in the first quarter. Bank of Nova Scotia now owns 134,074 shares of the medical instruments supplier’s stock valued at $24,595,000 after buying an additional 64,251 shares during the last quarter. 75.57% of the stock is owned by institutional investors.

Becton, Dickinson and Company (BDX) traded up 0.24% on Tuesday, reaching $202.25. 235,918 shares of the company’s stock were exchanged. The stock has a market capitalization of $46.02 billion, a PE ratio of 58.57 and a beta of 1.05. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $206.63. The firm has a 50 day moving average of $199.09 and a 200 day moving average of $188.17.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.35 earnings per share. Equities analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.45%. Becton, Dickinson and’s payout ratio is 83.43%.

ILLEGAL ACTIVITY WARNING: “HM Payson & Co. Sells 389 Shares of Becton, Dickinson and Company (BDX)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.watchlistnews.com/hm-payson-co-sells-389-shares-of-becton-dickinson-and-company-bdx/1491847.html.

Several equities research analysts have recently issued reports on the stock. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday. Cowen and Company reissued a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a research report on Monday. Barclays PLC reissued an “equal weight” rating and issued a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Finally, Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $195.79.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the sale, the insider now owns 12,861 shares in the company, valued at $2,538,890.01. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the sale, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,482 shares of company stock worth $9,871,556. 1.40% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.